TM5614, an Inhibitor of Plasminogen Activator Inhibitor-1, Exerts an Antitumor Effect on Chronic Myeloid Leukemia

TM5614, an Inhibitor of Plasminogen Activator Inhibitor-1, Exerts an Antitumor Effect on Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is triggered by t(9;22)(q34;q11.2) translocation, leading to the formation of the BCR-ABL1 fusion gene. Although the development of BCR-ABL1 tyrosine kinase inhibitors (TKIs) has dramatically improved the prognosis of CML, the disease could often relapse, presumably be...

Full description

Bibliographic Details
Main Authors: Fujiwara, T. (Author), Fukuhara, N. (Author), Harigae, H. (Author), Ichikawa, S. (Author), Kato, H. (Author), Miyata, T. (Author), Ochi, T. (Author), Onishi, Y. (Author), Ono, K. (Author), Onodera, K. (Author), Sasaki, K. (Author), Yokoyama, H. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
apoptosis
Apoptosis
chronic myeloid leukemia
drug resistance
Drug Resistance, Neoplasm
furin
Furin
FURIN
genetics
human
Humans
K-562 cell line
K562 Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
matrix metalloproteinase 14
Matrix Metalloproteinase 14
messenger RNA
NOTCH1 signaling
pathology
plasminogen activator inhibitor 1
Plasminogen Activator Inhibitor 1
plasminogen activator inhibitor-1
protein kinase inhibitor
Protein Kinase Inhibitors
RNA, Messenger
TM5614
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items